Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 8:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,768 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Sanofi Clear all
Terminated Phase 1 Interventional

Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias

NCT00852709
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Disorders, Acute Lymphocytic Leukemia, Acute Promyelocytic Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia
Interventions
Clofarabine, Cyclophosphamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
1 Year to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Phoenix, Arizona • Aurora, Colorado • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 16, 2026, 8:27 PM EDT
Completed Phase 2 Interventional Results available

Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia

NCT00328198
View directory record Official record
Conditions
B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Interventions
Alemtuzumab
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
7
States / cities
La Jolla, California • La Verne, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 16, 2026, 8:27 PM EDT
Completed Phase 2 Interventional Results available

A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)

NCT00373529
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Myeloid Leukemia
Interventions
clofarabine
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
60 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 16, 2026, 8:27 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride

NCT02263547
View directory record Official record
Conditions
Teriflunomide Elimination, Healthy Volunteers
Interventions
teriflunomide, Colestipol
Drug
Lead sponsor
Derrick Scott Robertson
Other
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 16, 2026, 8:27 PM EDT
Completed Phase 2 Interventional

Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel

NCT01332656
View directory record Official record
Conditions
Ovarian Cancer Recurrent
Interventions
Ombrabulin (AVE8062), Placebo, Paclitaxel, Carboplatin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Burbank, California • New Haven, Connecticut • Fort Meyers, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 16, 2026, 8:27 PM EDT
Completed Phase 3 Interventional

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

NCT00305188
View directory record Official record
Conditions
Metastases, Colorectal Neoplasms, Colorectal Carcinoma
Interventions
Xaliproden (SR57746A), Placebo, Oxaliplatin, 5-Fluorouracil, Leucovorin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 16, 2026, 8:27 PM EDT
Recruiting Phase 2 Interventional

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

NCT07170917
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Brivekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Northridge, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 16, 2026, 8:27 PM EDT
Completed Phase 4 Interventional Results available

Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital

NCT01203774
View directory record Official record
Conditions
Diabetes
Interventions
Glargine insulin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
22 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 16, 2026, 8:27 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older

NCT07734649
View directory record Official record
Conditions
Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
Interventions
RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4, Control Vaccine 2, Placebo, Control Vaccine 1
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
60 Years and older
Enrollment
2,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
50
States / cities
Gadsden, Alabama • Vestavia Hills, Alabama • Huntington Beach, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 16, 2026, 8:27 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

NCT00021255
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Doxorubicin, Cyclophosphamide, Docetaxel, Herceptin, Carboplatin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
3,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2014
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 16, 2026, 8:27 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

NCT01084252
View directory record Official record
Conditions
Hematological Malignancy
Interventions
Isatuximab SAR650984, Dexamethasone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2023
U.S. locations
16
States / cities
Scottsdale, Arizona • San Francisco, California • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 16, 2026, 8:27 PM EDT
Completed Phase 1 Interventional

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

NCT02332850
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Carfilzomib, Dexamethasone
Biological · Drug
Lead sponsor
Thomas Martin, MD
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
5
States / cities
San Francisco, California • Denver, Colorado • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 16, 2026, 8:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne

NCT07013747
View directory record Official record
Conditions
Acne
Interventions
Acne mRNA vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Encino, California • Brandon, Florida • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 16, 2026, 8:27 PM EDT
Terminated Phase 4 Interventional

KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections

NCT00132951
View directory record Official record
Conditions
Respiratory Tract Infections, Chronic Bronchitis, Pneumonia
Interventions
Telithromycin, Azithromycin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 35 Years
Enrollment
2,051 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 27, 2009 · Synced Oct 16, 2026, 8:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

NCT04551677
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 84 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 16, 2026, 8:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis

NCT04718870
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Dupilumab SAR231893
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 11 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Los Angeles, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 16, 2026, 8:27 PM EDT
Completed Phase 3 Interventional Results available

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

NCT03417245
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
fitusiran, factor concentrates
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
12 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Little Rock, Arkansas • Gainesville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 16, 2026, 8:27 PM EDT
Completed Phase 3 Interventional Results available

A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb

NCT00398866
View directory record Official record
Conditions
Osteoarthritis
Interventions
Synvisc (Hylan G-F20; hyaluronan injection), Bupivicaine (local anesthesia injection), Kenalog (triamcinolone; corticosteroid injection)
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years to 95 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 16, 2026, 8:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Acceptability of Fluzone Intradermal Vaccine to Patients and Vaccine Administrators

NCT01716130
View directory record Official record
Conditions
Patient Response to Fluzone ID Vaccine
Interventions
Not listed
Lead sponsor
Touro University, California
Other
Eligibility
18 Years to 64 Years
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Vallejo, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Oct 16, 2026, 8:27 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX

NCT00314145
View directory record Official record
Conditions
Japanese Encephalitis
Interventions
ChimeriVax™-JE, JE-VAX®
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
820 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
5
States / cities
Chicago, Illinois • Shawnee Mission, Kansas • Missoula, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 16, 2026, 8:27 PM EDT
Completed Phase 2 Interventional

Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)

NCT00115375
View directory record Official record
Conditions
Congenital Heart Defects, Blood Platelet Disorders
Interventions
Clopidogrel (SR25990)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Up to 24 Months
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 16, 2026, 8:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects

NCT04451954
View directory record Official record
Conditions
Influenza Immunisation, Healthy Volunteers
Interventions
Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 1 and adjuvant, Quadrivalent RIV with H3 strain 2, Quadrivalent RIV with H3 strain 2 and adjuvant, Quadrivalent RIV with 2018-2019 NH H3 strain, Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
5
States / cities
San Diego, California • Melbourne, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 16, 2026, 8:27 PM EDT
Completed Phase 2 Interventional Results available

Trial of High-Dose Rifampin in Patients With TB

NCT01408914
View directory record Official record
Conditions
Tuberculosis
Interventions
Higher-Dose Rifampin
Drug
Lead sponsor
Harvard University Faculty of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 16, 2026, 8:27 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of rFVIIIFc at Two Vial Strengths

NCT02083965
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
rFVIIIFc
Biological
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
12 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 16, 2026, 8:27 PM EDT